Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PhagoDAIR I
2024-516207-17-00Phase 2Completed
- Sponsor
- PHAXIAM Therapeutics
- Start
- Aug 2024
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of PP1493 and PP1815 in periprosthetic joint infection (PJI) (2 arms), sponsored by PHAXIAM Therapeutics. Primary endpoints: Clinical control of infection, Periarticular inflammatory and infectious clinical signs and 1 more. Started Aug 2024; status: completed.
02
Drugs
PP1493PP1815
03
Conditions
periprosthetic joint infection (PJI)
Beyond the preview
Go deeper on 2024-516207-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516207-17-00.